Given the fact that AHR inhibition enhanced progenitor and stem cell proliferation in CML patients, its activation could be a potential therapeutic target to reduce and eliminate leukemic stem cells. This evidence concerns the gene AHR and chronic myelogenous leukemia, BCR-ABL1 positive.